Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.

ABSTRACT: Schizophrenia is a chronic psychiatric disorder which substantially impairs patients' quality of life. Despite the extensive research in this field, the pathophysiology and etiology of schizophrenia remain unknown. Different neurotransmitter systems and functional networks have been found to be affected in the brain of patients with schizophrenia. In this context, postmortem brain studies as well as genetic assays have suggested alterations in Group II metabotropic glutamate receptors (mGluRs) in schizophrenia. Despite many years of drug research, several needs in the treatment of schizophrenia have not been addressed sufficiently. In fact, only 5-10% of patients with schizophrenia successfully achieve a full recovery after treatment. In recent years mGluRs have turned up as novel targets

SUBMITTER: Muguruza C 

PROVIDER: S-EPMC4873505 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature